Cargando…

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study

BACKGROUND & OBJECTIVES: Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goni, Deepak, Jain, Arihant, Singh, Charanpreet, Jindal, Nishant, Nampoothiri, Ram, Jandial, Aditya, Lad, Deepesh, Khadwal, Alka, Prakash, Gaurav, Naseem, Shano, Varma, Neelam, Malhotra, Pankaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Practice: Short Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284370/ https://www.ncbi.nlm.nih.gov/pubmed/37040232 http://dx.doi.org/10.4103/ijmr.ijmr_1090_21

Ejemplares similares

Chronic Lymphocytic Leukemia: Real-World Data From India
por: Tejaswi, V., et al.
Publicado: (2020)

Variation in Adherence Measures to Imatinib Therapy
por: Yanamandra, Uday, et al.
Publicado: (2017)

CostPlus and implications for generic imatinib
por: Jenei, Kristina, et al.
Publicado: (2022)

Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial)
por: Singh, Charanpreet, et al.
Publicado: (2022)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
por: Jain, Arihant, et al.
Publicado: (2020)

Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
por: Prakash, Gaurav, et al.
Publicado: (2021)

Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression
por: Srinivasan, Vishrut K., et al.
Publicado: (2020)

PB1909: A STUDY ON TROUGH LEVELS OF GENERIC DASATINIB AND ITS CORRELATION WITH ADVERSE EVENTS AND EFFICACY.
por: Nair, A., et al.
Publicado: (2022)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Outcome of Frontline Treatment with “Generic” Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study
por: Entasoltan, B., et al.
Publicado: (2017)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Short Research Communication Anti-Spike Antibody Response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients
por: Chopra, Madhu, et al.
Publicado: (2022)

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
por: Padula, William V., et al.
Publicado: (2016)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
por: Chen, Li-Chia, et al.
Publicado: (2013)

Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance
por: Nair, Ashwin, et al.
Publicado: (2023)

Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation
por: Khaire, Niranjan S., et al.
Publicado: (2021)

Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase
por: Malhotra, Hemant, et al.
Publicado: (2015)

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
por: Chen, Teng-Chou, et al.
Publicado: (2013)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
por: Gordois, A, et al.
Publicado: (2003)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
por: Bombeccari, Gian Paolo, et al.
Publicado: (2017)

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
por: Horne, G. A., et al.
Publicado: (2020)

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets
por: Arora, Rachna, et al.
Publicado: (2016)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
por: Halbach, Sebastian, et al.
Publicado: (2013)

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells
por: Sheng, Yaru, et al.
Publicado: (2019)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Imatinib-induced pancreatitis
por: Varma, Mahesh R., et al.
Publicado: (2010)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia
por: Zhu, Jiewen, et al.
Publicado: (2013)

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy
por: Newcott, Eric K., et al.
Publicado: (2015)

Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro
por: Husaini, Roslina, et al.
Publicado: (2017)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Complications and management of coagulation disorders in leukemia patients
por: Lad, Deepesh, et al.
Publicado: (2017)

Safety and efficacy of Vitamin D(3) supplementation with Imatinib in Chronic Phase- Chronic Myeloid Leukaemia: an Exploratory Randomized Controlled Trial
por: Bandyopadhyay, Arkapal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1l3uca4ret9accbg9rd4flai4